Ipremom's blood test reads first-trimester risk of later pregnancy complications

Femtech diagnostics: blood tests that identify future-complication risk early in pregnancy.

That a simple blood test in the first trimester can flag which pregnancies will develop serious complications — turning late-emergency care into early management.

€15m seed round.

The Spanish startup developed a blood test that can identify risks of future complications for mothers from the first trimester of pregnancy.

The test reads future-complication risk from the first trimester, when intervention options are widest.

A €15m seed is a sizable early bet for a Spanish femtech company, reported as a Sifted exclusive.

Standard pregnancy care tends to find complications late; the product's value is the time it buys.

Move the diagnosis earlier than the symptom: in pregnancy, predicting at week 12 changes decisions months before risk becomes emergency.

As of the report the company had new seed capital to develop its test; no clinical or commercial milestones were disclosed.